Search research articles
Contact Us
Filters
Showing results (51-60 of 76) with videos related to
Page
of 8
Sort By:
ESMO Open
|
September 29, 2023
Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial
E Grassi, C Zingaretti, E Petracci, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 4, 2018
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation
F Morano, S Corallo, M Niger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2025
Risk of disease progression in the first-line therapy of metastatic colorectal cancer to guide disease re-assessments - analysis of eleven trials by AIO and GONO
M M Germani, V Heinemann, D Rossini, et al.
Cancer Medicine
|
March 7, 2023
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials
G Martini, D Ciardiello, V Famiglietti, et al.
ESMO Open
|
June 25, 2026
Distinct molecular and clinical aggressiveness in very early-onset metastatic colorectal cancer: survival and genomic divergence between patients aged 30-39 versus 40-49 years
A Pretta, G Rebecchi, G Maddalena, et al.
International Journal of Cancer
|
September 1, 2016
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research
F Pietrantonio, M Caporale, F Morano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 27, 2015
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer
L Barault, A Amatu, F E Bleeker, et al.
ESMO Open
|
February 26, 2026
Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma
K Shitara, Y-J Bang, L S Wyrwicz, et al.
ESMO Open
|
June 10, 2026
Anti-EGFR-based maintenance versus stop and go in patients with left-sided, non-MSI-H, RAS/BRAF-wt metastatic colorectal cancer: individual patient data pooled analysis
A Raimondi, G Tinè, V Boige, et al.
ESMO Open
|
June 12, 2025
Sexual health in cancer care: a narrative review and position statement from the Italian Association of Medical Oncology (AIOM)
A Rossi, A G Leone, M Lambertini, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 76) with videos related to
Sort By:
Page
of 8
ESMO Open
|
September 29, 2023
Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial
E Grassi, C Zingaretti, E Petracci, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 4, 2018
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation
F Morano, S Corallo, M Niger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2025
Risk of disease progression in the first-line therapy of metastatic colorectal cancer to guide disease re-assessments - analysis of eleven trials by AIO and GONO
M M Germani, V Heinemann, D Rossini, et al.
Cancer Medicine
|
March 7, 2023
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials
G Martini, D Ciardiello, V Famiglietti, et al.
ESMO Open
|
June 25, 2026
Distinct molecular and clinical aggressiveness in very early-onset metastatic colorectal cancer: survival and genomic divergence between patients aged 30-39 versus 40-49 years
A Pretta, G Rebecchi, G Maddalena, et al.
International Journal of Cancer
|
September 1, 2016
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research
F Pietrantonio, M Caporale, F Morano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 27, 2015
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer
L Barault, A Amatu, F E Bleeker, et al.
ESMO Open
|
February 26, 2026
Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma
K Shitara, Y-J Bang, L S Wyrwicz, et al.
ESMO Open
|
June 10, 2026
Anti-EGFR-based maintenance versus stop and go in patients with left-sided, non-MSI-H, RAS/BRAF-wt metastatic colorectal cancer: individual patient data pooled analysis
A Raimondi, G Tinè, V Boige, et al.
ESMO Open
|
June 12, 2025
Sexual health in cancer care: a narrative review and position statement from the Italian Association of Medical Oncology (AIOM)
A Rossi, A G Leone, M Lambertini, et al.
Page
of 8